Business Description
Founded in 2016 and based in San Francisco, Vir Biotechnology is a clinical-stage company focused on developing treatments and preventions for serious infectious diseases across global markets. Its pipeline includes therapies targeting hepatitis delta virus, various solid tumors, influenza, and coronavirus, among other conditions. The company works alongside a broad network of partners, including Alnylam Pharmaceuticals, GlaxoSmithKline, the Gates Foundation, and several other research institutions and biotechnology firms.
